Zobrazeno 1 - 10
of 79
pro vyhledávání: ''
Autor:
Jos H. Beijnen, Alwin D. R. Huitema, Philip C. Schouten, Sabine C. Linn, Jan H.M. Schellens, Katarzyna Jóźwiak, Serena Marchetti, Gwen M. H. E. Dackus, Jill J.J. Geenen, Gabe S. Sonke, Dick Pluim
Publikováno v:
International Journal of Cancer
Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olapa
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1623-1633 (2021)
Cancer Medicine
Cancer Medicine
Background Metabolomics is the newest ‐omics methodology and allows for a functional snapshot of the biochemical activity and cellular state. The goal of this study is to characterize metabolomic profiles associated with cancer‐related fatigue, a
Autor:
Sung Shim Cho, Hyunho Kim, Yoon Ho Ko, Byoung Yong Shim, Ho Jung An, Hye Sung Won, Der Sheng Sun, Hyung Soon Park
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 1057-1065 (2021)
Cancer Medicine
Cancer Medicine
Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective coho
Autor:
Kai Dun Tang, Touraj Taheri, Brett G.M. Hughes, Chamindie Punyadeera, Liz Kenny, Gert Scheper, Sarju Vasani, Laurence J. Walsh, Lilian Menezes, Ian H. Frazer
Publikováno v:
Cancer Science
Given that oropharyngeal squamous cell carcinoma (OPSCC) have now surpassed cervical cancer as the most common human papillomavirus (HPV)‐driven cancer, there is an interest in developing non‐invasive predictive biomarkers to early detect HPV‐d
Autor:
Tomoyuki Endo, Shinsuke Iida, Noriko Fukuhara, Yasuhito Terui, Wataru Munakata, Hiroshi Handa, Noriko Iwaki, Shinya Rai, Naohiro Sekiguchi, Koji Izutsu, Hirohiko Shibayama, Kenshi Suzuki, Hiro Tatetsu, Takayuki Ishikawa, Ryota Shiibashi
Publikováno v:
Cancer Sci
Cancer Science
Cancer Science
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refra
Publikováno v:
Cancer Medicine, Vol 9, Iss 16, Pp 5899-5907 (2020)
Cancer Medicine
Cancer Medicine
Background This study aimed to evaluate the efficacy and safety of apatinib with a low dose of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer patients. Methods Patients with platinum‐resistant or platinum
Autor:
William T. Barry, Shannon N. Westin, Vicky Makker, Weixiu Luo, Michael J. Birrer, Funda Meric-Bernstam, Russell Broaddus, Robert L. Coleman, Andrea P. Myers, Joyce F. Liu, Carol Aghajanian, Panagiotis A. Konstantinopoulos, Austin Doyle, Neil S. Horowitz, Ursula A. Matulonis, Ronny Drapkin, Gordon B. Mills, Lewis C. Cantley
Publikováno v:
Int J Cancer
Endometrial cancers have high rates of phosphoinositide 3-kinase (PI3K) pathway alterations. MK-2206 is an allosteric inhibitor of AKT, an effector kinase of PI3K signals. We hypothesized patients with tumors harboring PIK3CA mutations would be more
Autor:
Masafumi Taniwaki, Koji Izutsu, Tadao Ishida, Takaaki Chou, Takashi Watanabe, Kenshi Suzuki, Naokuni Uike, Kiyohiko Hatake, Kensei Tobinai, Yoshihisa Shumiya, Takayuki Ishikawa, Kazutaka Sunami, Kiyoshi Ando, Morio Matsumoto, Shuji Ozaki, Hirohiko Shibayama, Shinsuke Iida
Publikováno v:
Cancer Science
This multicenter, open‐label phase 1/2 study evaluated single‐agent carfilzomib in 50 heavily pretreated Japanese patients with relapsed/refractory multiple myeloma (median of five prior treatments). In phase 1, patients were dosed at three level
Autor:
Salah-Eddin Al-Batran, Thomas J. Ettrich, Holger Schulz, Nadine Schulte, Janja Ocvirk, Hans-Peter Feustel, Kirsten Merx, Melanie Kripp, Michael Schatz, Ralf-Dieter Hofheinz, Winfried Koch, Steffen Heeger, Maria Rita Gaiser, Joerg Trojan, S. Lorenzen, Nils Homann, Soetkin Vlassak
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 9, Pp 4169-4175 (2019)
Cancer Medicine, Vol 8, Iss 9, Pp 4169-4175 (2019)
Acne-like skin reactions frequently occur in patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor. Recently, the effects of vitamin K1 containing cream (Reconval K1) as prophylactic skin treatment in addition to do
Autor:
Anna Kopińska, Iwona Hus, Wieslaw Wiktor-Jedrzejczak, Andrzej Szczepaniak, Piotr Smolewski, Dariusz Wołowiec, Wanda Knopinska-Posluszny, Justyna Rybka, Olga Grzybowska-Izydorczyk, Kazimierz Hałaburda, Anna Waszczuk-Gajda, Sebastian Giebel, Krzysztof Jamroziak, Jadwiga Hołojda, Joanna Drozd-Sokołowska, Jacek Kwiatkowski, Magdalena Witkowska, Tomasz Żółtak, Edyta Subocz, Jan Maciej Zaucha, Maciej Kaźmierczak
Publikováno v:
Hematological Oncology. 37:383-391
Richter transformation (RT) of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) to Hodgkin lymphoma (HL) is a rare and unexpected event in the course of the disease and data on this phenomenon is still limited. To better understand t